ATE269699T1 - Methoden zur regulierung der grösse und des wachstums von durchblutetem normalem gewebe - Google Patents
Methoden zur regulierung der grösse und des wachstums von durchblutetem normalem gewebeInfo
- Publication number
- ATE269699T1 ATE269699T1 AT98967012T AT98967012T ATE269699T1 AT E269699 T1 ATE269699 T1 AT E269699T1 AT 98967012 T AT98967012 T AT 98967012T AT 98967012 T AT98967012 T AT 98967012T AT E269699 T1 ATE269699 T1 AT E269699T1
- Authority
- AT
- Austria
- Prior art keywords
- adipose tissue
- tissue
- angiogenesis inhibitors
- growth
- endometriosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Laser Surgery Devices (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6444597P | 1997-10-31 | 1997-10-31 | |
PCT/US1998/022998 WO1999039702A2 (en) | 1997-10-31 | 1998-10-30 | Method for regulating size and growth of vascularized normal tissue |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE269699T1 true ATE269699T1 (de) | 2004-07-15 |
Family
ID=22056030
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT98967012T ATE269699T1 (de) | 1997-10-31 | 1998-10-30 | Methoden zur regulierung der grösse und des wachstums von durchblutetem normalem gewebe |
Country Status (9)
Country | Link |
---|---|
US (1) | US6306819B1 (de) |
EP (1) | EP1024801B1 (de) |
JP (2) | JP2002502814A (de) |
AT (1) | ATE269699T1 (de) |
AU (1) | AU3352799A (de) |
CA (1) | CA2307792C (de) |
DE (1) | DE69824750T2 (de) |
ES (1) | ES2224465T3 (de) |
WO (1) | WO1999039702A2 (de) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001285919B2 (en) | 2000-09-05 | 2007-08-23 | Jiangsu Simcere Pharmaceutical R&D Co., Ltd | Recombinant endothelial cell growth inhibitors derived from a mammalian plasminogen |
CA2445969A1 (en) * | 2001-04-30 | 2002-11-07 | Cell Genesys, Inc. | Viral-mediated delivery and in vivo expression of polynucleotides encoding anti-angiogenic proteins |
WO2003057235A2 (en) * | 2002-01-10 | 2003-07-17 | Imperial College Innovations Ltd | Modification of feeding behavior |
US7790670B2 (en) | 2002-03-01 | 2010-09-07 | Glanbia Nutritionals (Ireland) Ltd. | Compositions and methods for treatment of body weight conditions |
US20030165574A1 (en) * | 2002-03-01 | 2003-09-04 | Ward Loren Spencer | Compositions and methods for treatment of body weight conditions |
US7365209B2 (en) * | 2003-02-11 | 2008-04-29 | Pharmacopeia, Inc. | Nitrogen heterocycle biaryls for osteoporosis and other diseases |
US7524811B2 (en) | 2003-08-29 | 2009-04-28 | Children's Medical Center Corporation | Anti-angiogenic peptides from the N-terminus of endostatin |
CA2537236A1 (en) * | 2003-08-29 | 2005-05-12 | Children's Medical Center Corporation | Anti-angiogenic peptides for treating or preventing endometriosis |
US20070172474A1 (en) * | 2004-04-02 | 2007-07-26 | University Of Tennessee Research Foundiation | Dairy components effective for fat loss |
KR20080007450A (ko) * | 2005-04-11 | 2008-01-21 | 유니버시티 오브 테네시 리서치 파운데이션 | 지방 감소에 효과적인 안정된 유제품 성분 |
WO2009021104A2 (en) * | 2007-08-08 | 2009-02-12 | Cavanaugh Brian J | Method and apparatus for delivery of a ligating suture |
CN102123586A (zh) * | 2008-07-18 | 2011-07-13 | 法弗根股份有限公司 | 治疗超重或肥胖受试者的方法 |
US8642650B2 (en) | 2008-12-04 | 2014-02-04 | Zafgen, Inc. | Methods of treating an overweight or obese subject |
WO2010065877A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
US20120010259A1 (en) * | 2008-12-04 | 2012-01-12 | Vath James E | Methods of Treating an Overweight or Obese Subject |
CN102639494B (zh) | 2009-10-09 | 2016-11-09 | 扎夫根公司 | 砜化合物及其制备和使用方法 |
US8772333B2 (en) | 2010-01-08 | 2014-07-08 | Zafgen, Inc. | Fumigillol type compounds and methods of making and using same |
US8815309B2 (en) | 2010-01-08 | 2014-08-26 | Zafgen, Inc. | Methods of treating a subject with benign prostate hyperplasia |
US20130266578A1 (en) | 2010-04-07 | 2013-10-10 | Thomas E. Hughes | Methods of treating an overweight subject |
US9895449B2 (en) | 2010-05-25 | 2018-02-20 | Syndevrx, Inc. | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof |
ES2853204T3 (es) | 2010-05-25 | 2021-09-15 | Syndevrx Inc | Inhibidores de MetAP2 conjugado con polímero, y métodos terapéuticos de uso de los mismos |
JP5913310B2 (ja) | 2010-07-22 | 2016-04-27 | ザフゲン,インコーポレイテッド | 三環式化合物ならびにその作製および使用方法 |
CN103347870A (zh) | 2010-11-09 | 2013-10-09 | 扎夫根股份有限公司 | Metap-2抑制剂的结晶固体及其制备和使用方法 |
WO2012075020A1 (en) | 2010-11-29 | 2012-06-07 | Zafgen Corporation | Treatment of obesity using non-daily administration of 6 - 0 - (4 - dimethylaminoethoxy) cinnamoyl fumagillol |
US9321740B2 (en) | 2011-01-26 | 2016-04-26 | Zafgen, Inc. | Tetrazole compounds and methods of making and using same |
MX342257B (es) * | 2011-03-08 | 2016-09-21 | Zafgen Inc | Derivados y análogos de oxaspiro [2.5] octano. |
KR20140053013A (ko) | 2011-05-06 | 2014-05-07 | 자프겐 인크. | 삼환식 설폰아마이드 화합물 그리고 그의 제조방법 및 그를 이용하는 방법 |
WO2012154679A1 (en) | 2011-05-06 | 2012-11-15 | Zafgen Corporation | Tricyclic pyrazole sulfonamide compounds and methods of making and using same |
WO2012154676A1 (en) | 2011-05-06 | 2012-11-15 | Zafgen Corporation | Partially saturated tricyclic compounds and methods of making and using same |
EP2763671A2 (de) | 2011-10-03 | 2014-08-13 | Zafgen, Inc. | Verfahren zur behandlung von altersbedingten erkrankungen |
WO2013109735A1 (en) | 2012-01-18 | 2013-07-25 | Zafgen, Inc. | Tricyclic sulfone compounds and methods of making and using same |
EP2804866B1 (de) | 2012-01-18 | 2016-11-16 | Zafgen, Inc. | Tricyclische sulfonamidverbindungen sowie verfahren zur herstellung und verwendung davon |
EP2847176A1 (de) | 2012-05-07 | 2015-03-18 | Zafgen, Inc. | Polymorphes salz des oxalatsalzes von 6-o-(4-dimethylaminoethoxy-)cinnarnoyl-fumagillol und verfahren zur herstellung und verwendung davon |
BR112014028041A2 (pt) | 2012-05-08 | 2017-06-27 | Zafgen Inc | tratamento de obesidade hipotalâmica com inibidores de metap2 |
WO2013169860A1 (en) | 2012-05-09 | 2013-11-14 | Zafgen, Inc. | Fumigillol type compounds and methods of making and using same |
JP2015536983A (ja) | 2012-11-05 | 2015-12-24 | ザフゲン,インコーポレイテッド | 肥満の治療及び抑制における三環式化合物の使用 |
AU2013337287B2 (en) | 2012-11-05 | 2017-03-23 | Zafgen, Inc. | Methods of treating liver diseases |
AU2013337282A1 (en) | 2012-11-05 | 2015-05-21 | Zafgen, Inc. | Tricyclic compounds and methods of making and using same |
BR112015023390A2 (pt) | 2013-03-14 | 2017-07-18 | Zafgen Inc | métodos para tratar de doença renal e outros distúrbios |
EA033912B1 (ru) | 2013-04-10 | 2019-12-09 | Синдевркс, Инк. | ИНГИБИТОРЫ MetAP2 И СПОСОБЫ ЛЕЧЕНИЯ ОЖИРЕНИЯ |
CA3003760A1 (en) * | 2014-11-03 | 2016-05-12 | Tsinghua University | Drug for inhibiting adipose cell differentiation and insulin resistance |
TW201636342A (zh) | 2014-12-19 | 2016-10-16 | 武田藥品工業有限公司 | 煙黴醇衍生物 |
CN106432255A (zh) | 2015-08-11 | 2017-02-22 | 扎夫根公司 | 烟曲霉素醇螺环化合物和制备和使用其的方法 |
AR105671A1 (es) | 2015-08-11 | 2017-10-25 | Zafgen Inc | Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso |
CA3005450A1 (en) | 2015-12-10 | 2017-06-15 | Syndevrx, Inc. | Fumagillol derivatives and polymorphs thereof |
CA3239447A1 (en) | 2016-01-11 | 2017-07-20 | Syndevrx, Inc. | Treatment for tumors driven by metabolic dysfunction |
EP3870231A1 (de) | 2018-10-26 | 2021-09-01 | Syndevrx, Inc. | Biomarker von metap2-inhibitoren und anwendungen davon |
CN116635060A (zh) * | 2020-10-23 | 2023-08-22 | Sk生物科学株式会社 | 包含编码外来抗原的遗传物质的用于减小靶组织的尺寸或体积的疫苗组合物或药盒 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02289532A (ja) * | 1989-02-27 | 1990-11-29 | Takeda Chem Ind Ltd | 生理活性物質tan―1085,そのアグリコン,製造法及び用途 |
US5290807A (en) | 1989-08-10 | 1994-03-01 | Children's Medical Center Corporation | Method for regressing angiogenesis using o-substituted fumagillol derivatives |
MX9401807A (es) * | 1993-03-12 | 1995-01-31 | Xoma Corp | Usos terapeuticos de productos de proteina que incrementan lapermeabilidad/bactericidas. |
US5443824A (en) * | 1994-03-14 | 1995-08-22 | Piacquadio; Daniel J. | Topical thalidomide compositions for surface or mucosal wounds, ulcerations, and lesions |
US5639725A (en) | 1994-04-26 | 1997-06-17 | Children's Hospital Medical Center Corp. | Angiostatin protein |
EP0721781B1 (de) * | 1994-12-15 | 2002-03-06 | Advance Biofactures Of Curacao N.V. | Verminderung des Fettgewebes durch Verwendung von Kollagenase |
JPH1029940A (ja) * | 1996-07-15 | 1998-02-03 | Kureha Chem Ind Co Ltd | エボジアミン誘導体含有hsp47合成抑制剤 |
WO1998005293A2 (en) * | 1996-08-02 | 1998-02-12 | The Children's Medical Center Corporation | Method of regulating the female reproductive system through angiogenesis inhibitors |
DE19631806A1 (de) * | 1996-08-07 | 1998-02-12 | Wella Ag | Sauerstoffschaum zur oxidativen Haarbehandlung |
US6034256A (en) * | 1997-04-21 | 2000-03-07 | G.D. Searle & Co. | Substituted benzopyran derivatives for the treatment of inflammation |
CA2291514C (en) * | 1997-05-30 | 2011-07-12 | Creative Biomolecules, Inc. | Methods for evaluating tissue morphogenesis and activity |
-
1998
- 1998-10-30 US US09/183,556 patent/US6306819B1/en not_active Expired - Lifetime
- 1998-10-30 DE DE69824750T patent/DE69824750T2/de not_active Expired - Lifetime
- 1998-10-30 AT AT98967012T patent/ATE269699T1/de not_active IP Right Cessation
- 1998-10-30 WO PCT/US1998/022998 patent/WO1999039702A2/en active IP Right Grant
- 1998-10-30 JP JP2000530201A patent/JP2002502814A/ja not_active Withdrawn
- 1998-10-30 EP EP98967012A patent/EP1024801B1/de not_active Expired - Lifetime
- 1998-10-30 AU AU33527/99A patent/AU3352799A/en not_active Abandoned
- 1998-10-30 CA CA002307792A patent/CA2307792C/en not_active Expired - Lifetime
- 1998-10-30 ES ES98967012T patent/ES2224465T3/es not_active Expired - Lifetime
-
2010
- 2010-09-21 JP JP2010211423A patent/JP2011026332A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
US6306819B1 (en) | 2001-10-23 |
JP2011026332A (ja) | 2011-02-10 |
CA2307792A1 (en) | 1999-08-12 |
JP2002502814A (ja) | 2002-01-29 |
WO1999039702A3 (en) | 1999-10-14 |
CA2307792C (en) | 2007-06-26 |
DE69824750T2 (de) | 2005-07-07 |
ES2224465T3 (es) | 2005-03-01 |
WO1999039702A2 (en) | 1999-08-12 |
AU3352799A (en) | 1999-08-23 |
EP1024801A2 (de) | 2000-08-09 |
DE69824750D1 (de) | 2004-07-29 |
EP1024801B1 (de) | 2004-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE269699T1 (de) | Methoden zur regulierung der grösse und des wachstums von durchblutetem normalem gewebe | |
Gorski et al. | Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin | |
Liu et al. | Role of nucleostemin in growth regulation of gastric cancer, liver cancer and other malignancies | |
Tammela | Endocrine treatment of prostate cancer | |
Olive et al. | New medical treatments for endometriosis | |
di Sant’Agnese | Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments | |
NO20084148L (no) | Fremgangsmåte og inretning for behandling av mikroskopiske rester av tumorer som er igjen i vev etter kirurgisk fjerning | |
Garnick | Hormonal therapy in the management of prostate cancer: from Huggins to the present | |
Choi et al. | Nitric oxide and tumor necrosis factor-α production by oleanolic acid via nuclear factor-κB activation in macrophages | |
RU2009113038A (ru) | Комбинированная лекарственная терапия для лечения ожирения | |
WO2001051604A3 (en) | Methods for identifying anti-cancer drug targets | |
MXPA02009745A (es) | Producto de combinacion que comprende una antiandrogeno no-esteroidal y un inhibidor de quinasa tirosina rfce. | |
DE69427830D1 (de) | Keime von kobalt-palladium zur thermischen behandlung von tumoren | |
JP2003525906A5 (de) | ||
Chen et al. | Role of Akt/protein kinase B in the activity of transcriptional coactivator p300 | |
NO974943L (no) | Angiostatinfragmenter, aggregert angiostatin og anvendelse derav | |
Levy et al. | Effect of arginine on tumor growth in rats | |
BARKER | Cofactor induced synthesis of D-glucose-6-phosphate: NADP oxidoreductase in the uterus | |
Pollard et al. | Dietary prevention of hormone refractory prostate cancer in Lobund-Wistar rats: a review of studies in a relevant animal model | |
Wolf | The molecular mechanism of the stimulaton of adipocyte differentiation by a glucocorticoid | |
Mariani et al. | Postmenopausal endometrial hyperplasia: role of danazol therapy | |
Gordillo et al. | [36] Hemangioma model for in vivo angiogenesis: Inducible oxidative stress and MCP-1 expression in EOMA Cells | |
Yoshiji et al. | Stimulatory effect of endogenous tissue inhibitor of metalloproteinases-1 (TIMP-1) overexpression on type IV collagen and laminin gene expression in rat mammary carcinoma cells | |
DE60121980D1 (de) | Verwendung von 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2-pentafluoroethyl)estra-4,9-dien-3-on zur herstellung eines medikaments zur behandlung von brust-, eierstock-, endometrium-krebs, myelom und meningiom | |
Harding et al. | Depression of alanine transaminase activity in the liver of rats bearing walker carcinoma 256 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |